rhBMP-2 Versus Autograft in Critical Size Tibial Defects
Public ClinicalTrials.gov record NCT00853489. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
RhBMP-2 vs. Autograft for Critical Size Tibial Defects: A Multicenter Randomized Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of our study is to evaluate the use of recombinant human bone morphogenetic protein 2 (RhBMP-2) as compared to standard ICBG in the treatment of severe open tibia fractures with a critical size bone defect (at least one centimeter in length compromising at least 50% of the circumference of the bone).
Study identification
- NCT ID
- NCT00853489
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Interventions
Device · Procedure
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2011
- Primary completion
- Feb 16, 2017
- Completion
- Feb 16, 2017
- Last update posted
- Oct 24, 2018
2011 – 2017
United States locations
- U.S. sites
- 13
- U.S. states
- 13
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSF Medical Center | San Francisco | California | 94115 | — |
| Denver Health and Hospital Authority | Denver | Colorado | 80204 | — |
| Florida Orthopaedic Institute / Tampa General & St. Joseph's Hospitals | Tampa | Florida | 33606 | — |
| University of Iowa Hospitals | Iowa City | Iowa | 52242 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| Hennepin County Medical Center | Minneapolis | Minnesota | 55715 | — |
| St. Louis Medical Center | St Louis | Missouri | 63110 | — |
| Carolinas Medical Center | Charlotte | North Carolina | 28232 | — |
| MetroHealth Medical Center | Cleveland | Ohio | 44109 | — |
| University of Oklahoma / OU Medical Center | Oklahoma City | Oklahoma | 73104 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Brooke Army Medical Center | Fort Sam Houston | Texas | 78234-6315 | — |
| University of Washington / Harborview Medical Center | Seattle | Washington | 98104-2499 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00853489, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 24, 2018 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00853489 live on ClinicalTrials.gov.